Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

CLDI

Calidi Biotherapeutics Inc

May 17 • 11:30AM ET

0.2352

Dollar change -0.0068
Percentage change -2.81	%

Healthcare • Biotechnology • USA • AMEX

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.01	Insider Own	49.29%	Shs Outstand	35.52M	Perf Week	-0.34%
Market Cap	11.98M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	25.82M	Perf Month	47.00%
Income	-21.75M	PEG	-	EPS next Q	-0.22	Inst Own	5.27%	Short Float	0.18%	Perf Quarter	-57.00%
Sales	0.00M	P/S	-	EPS this Y	56.65%	Inst Trans	-85.86%	Short Ratio	0.04	Perf Half Y	-88.75%
Book/sh	-0.41	P/B	-	EPS next Y	62.67%	ROA	-85.99%	Short Interest	0.05M	Perf Year	-97.70%
Cash/sh	0.02	P/C	9.66	EPS next 5Y	-	ROE	-212.68%	52W Range	0.14 - 13.79	Perf YTD	-84.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-98.29%	Beta	0.73
Dividend TTM	-	Quick Ratio	0.13	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	63.90%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	0.13	EPS Y/Y TTM	-211.52%	Oper. Margin	0.00%	RSI (14)	42.52	Volatility	11.70% 19.02%
Employees	41	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	9.77%	Payout	-	Rel Volume	0.24	Prev Close	0.24
Sales Surprise	-	EPS Surprise	27.27%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	1.07M	Price	0.24
SMA20	16.87%	SMA50	-42.05%	SMA200	-90.99%	Trades		Volume	86,986	Change	-2.81%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-23	Initiated	H.C. Wainwright	Buy	$11
Oct-09-23	Initiated	Robert W. Baird	Outperform	$9

Today 09:00AM	Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV (ACCESSWIRE)
May-14-24 04:05PM	Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results (Business Wire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +7.95%
May-01-24 07:00AM	Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (Business Wire)
Apr-23-24 07:00AM	Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24 (Business Wire) +7.05%
04:05PM	Loading…
Apr-19-24 04:05PM	Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering (Business Wire)
Apr-16-24 08:31AM	Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering (Business Wire) -65.48%
Apr-09-24 07:00AM	Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Companys Novel Immunotherapies at the AACR Annual Meeting 2024 (Business Wire) +62.39%
Mar-15-24 04:05PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results (Business Wire)
Mar-11-24 07:00AM	Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer (Business Wire)
Feb-12-24 07:00AM	Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference (Business Wire)
Jan-08-24 07:00AM	Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board (Business Wire) +6.84%
Dec-13-23 07:00AM	Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit (Business Wire)
Dec-12-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors (Business Wire)
Nov-20-23 07:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones (Business Wire)
04:05PM	Loading…
Nov-14-23 04:05PM	Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results (Business Wire) -6.98%
Nov-03-23 07:00AM	Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancers 38th Annual Meeting (SITC 2023) (Business Wire) +18.90%
Nov-01-23 07:00AM	Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment (Business Wire) -10.55%
Oct-30-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer (Business Wire) -13.19%
Oct-10-23 07:00AM	Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023 (Business Wire)
Sep-13-23 05:50AM	Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies (GlobeNewswire) -38.75%
Sep-11-23 04:05PM	First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments (GlobeNewswire)
Aug-24-23 12:06PM	FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET (GlobeNewswire)
Aug-22-23 11:41AM	FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET (GlobeNewswire) -10.85%
Aug-16-23 06:00AM	Flag Stockholders: Reminder to Vote for Proposed Business Combination (GlobeNewswire)
Aug-07-23 05:00AM	First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination (GlobeNewswire)
Jun-23-23 05:00AM	Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer (GlobeNewswire)

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDI

Calidi Biotherapeutics Inc

Upgrade your FINVIZ experience